CA2959094A1 - Neprilysin as heart failure prognostic marker - Google Patents

Neprilysin as heart failure prognostic marker Download PDF

Info

Publication number
CA2959094A1
CA2959094A1 CA2959094A CA2959094A CA2959094A1 CA 2959094 A1 CA2959094 A1 CA 2959094A1 CA 2959094 A CA2959094 A CA 2959094A CA 2959094 A CA2959094 A CA 2959094A CA 2959094 A1 CA2959094 A1 CA 2959094A1
Authority
CA
Canada
Prior art keywords
nep
soluble
vitro method
heart failure
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2959094A
Other languages
English (en)
French (fr)
Inventor
Antoni BAYES GENIS
Josep Lupon Roses
Amparo Galan Ortega
Jaume Barallat Martinez De Osaba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Original Assignee
Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP filed Critical Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Publication of CA2959094A1 publication Critical patent/CA2959094A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96497—Enkephalinase (3.4.24.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CA2959094A 2014-08-29 2015-08-14 Neprilysin as heart failure prognostic marker Abandoned CA2959094A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14182846.7A EP2990800A1 (en) 2014-08-29 2014-08-29 Neprilysin as heartfailure (HF) prognostic marker
EP14182846.7 2014-08-29
PCT/EP2015/068729 WO2016030209A1 (en) 2014-08-29 2015-08-14 Neprilysin as heart failure prognostic marker

Publications (1)

Publication Number Publication Date
CA2959094A1 true CA2959094A1 (en) 2016-03-03

Family

ID=51421966

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2959094A Abandoned CA2959094A1 (en) 2014-08-29 2015-08-14 Neprilysin as heart failure prognostic marker

Country Status (11)

Country Link
US (1) US10203341B2 (enExample)
EP (2) EP2990800A1 (enExample)
JP (1) JP6661216B2 (enExample)
CN (1) CN107076758B (enExample)
AU (1) AU2015309112A1 (enExample)
CA (1) CA2959094A1 (enExample)
ES (1) ES2734876T3 (enExample)
MX (1) MX2017002453A (enExample)
RU (1) RU2017109086A (enExample)
SG (1) SG11201701393YA (enExample)
WO (1) WO2016030209A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021090909A1 (ja) * 2019-11-06 2021-05-14 国立大学法人 香川大学 心不全マーカー

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549019A (en) * 2001-09-03 2008-05-30 Intreat Pty Ltd Antibody that binds to a P2X7 receptor in which proline at position 210 is in a cis conformation
NZ599773A (en) * 2009-11-07 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2360280A1 (en) * 2010-02-24 2011-08-24 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Genetic marker for the diagnosis of dementia with Lewy bodies
US20120219943A1 (en) * 2011-02-03 2012-08-30 Abbott Laboratories Methods of prognosis and diagnosis in chronic heart failure
JP5945063B2 (ja) * 2012-04-12 2016-07-05 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 慢性心不全が疑われる患者における有害事象の予後
SI2887961T1 (sl) * 2012-08-24 2021-08-31 Novartis Ag Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju
WO2014116708A1 (en) * 2013-01-22 2014-07-31 Singulex, Inc. Endothelin in the diagnosis of cardiac disease
WO2014126972A1 (en) * 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
NZ710574A (en) * 2013-02-14 2017-11-24 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors

Also Published As

Publication number Publication date
US10203341B2 (en) 2019-02-12
MX2017002453A (es) 2017-10-23
JP6661216B2 (ja) 2020-03-11
AU2015309112A1 (en) 2017-04-06
RU2017109086A (ru) 2018-10-01
SG11201701393YA (en) 2017-03-30
US20170254815A1 (en) 2017-09-07
RU2017109086A3 (enExample) 2019-03-06
ES2734876T3 (es) 2019-12-12
EP3186639A1 (en) 2017-07-05
CN107076758A (zh) 2017-08-18
EP2990800A1 (en) 2016-03-02
WO2016030209A1 (en) 2016-03-03
CN107076758B (zh) 2019-10-22
EP3186639B1 (en) 2019-03-20
JP2017526924A (ja) 2017-09-14

Similar Documents

Publication Publication Date Title
DK2386860T3 (en) Prediction of mortality and detection of severe illness
US11307209B2 (en) Method diagnosis of a prenatal disorder by selective determination of placental growth factor 2
Motiwala et al. Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure
KR20160116060A (ko) 특정 시기 내에 임신중독증의 개시를 배제하기 위한 sFlt-1/PlGF 또는 엔도글린/PlGF 비의 적용 수단 및 방법
KR20170072215A (ko) 생물마커 및 예측 방법
US20250244317A1 (en) Assessment of preeclampsia using assays for free and dissociated placental growth factor
EP3497450A1 (en) Histones and/or proadm as markers indicating organ dysfunction
Kavsak et al. The potential role of a turbidimetric heart-type fatty acid-binding protein assay to aid in the interpretation of persistently elevated, non-changing, cardiac troponin I concentrations
Chang et al. Utility of the serum free light chain assay in the diagnosis of light chain amyloidosis in patients with heart failure
Anunciación-Llunell et al. The absence of standardization in antiphospholipid antibody testing may favor the use of 99th percentile cutoffs in antiphospholipid syndrome classification
WO2021113710A1 (en) Assessment of preeclampsia using assays for free and dissociated placental growth factor
JP7540074B2 (ja) Ｃｏｖｉｄ－１９患者の疾患重症度を予測するためのｇｄｆ－１５
Lapić et al. Interfering heterophile antibodies as the cause of persistently falsely elevated high-sensitivity troponin I on Alinity i: a case report
US10203341B2 (en) Neprilysin as heart failure prognostic marker
WO2020064995A1 (en) Use of biomarkers representing cardiac, vascular and inflammatory pathways for the prediction of acute kidney injury in patients with type 2 diabetes
EP3311164B1 (en) Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
CN111065922A (zh) 肾上腺髓质素原作为危重病患者的肾脏替代治疗的指标
Kloska et al. Reference values and biological determinants for cardiac myosin-binding protein C concentrations assessed with an enzyme-linked immunosorbent assay
US11112414B2 (en) Biomarker of rehospitalization after heart failure
US20140274975A1 (en) Method of determining prior history of ischemic stroke for current risk evaluation and therapy guidance
Masrouri et al. Longitudinal trajectories of albuminuria and risk of subclinical and clinical heart failure, atrial fibrillation, and coronary heart disease: the MESA study
CN121532655A (zh) 用于调节免疫测定信号的方法、试剂和试剂盒
US20190250172A1 (en) Prognosis of adverse outcomes by determination of midkine levels after cardiovascular stress
Class et al. Patent application title: Biomarker of Rehospitalization After Heart Failure Inventors: Philippe Rouet (Toulouse Cedex 4, FR) Fatima Smith-Rouet (Toulouse Cedex 4, FR) Franck Desmoulin (Toulouse Cedex 4, FR) Michel Galinier (Toulouse Cedex 4, FR)
Headquarters et al. Add Consistency to Monoclonal Gammopathy Testing: N Latex FLC kappa and lambda Assays

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20200831